Genetics of Outcome after SAH (GO-SAH)

Whole-genome sequencing (WGS) offers key advantages over array-based and exome sequencing approaches, particularly for complex traits like recovery after aneurysmal subarachnoid haemorrhage (aSAH). Most genetic signals identified in GWAS, including preliminary findings in our aSAH GWAS of ouctome, lie in noncoding regions that regulate gene expression—regions that WGS can interrogate but arrays and whole-exome sequencing cannot. Furthermore WGS also supports burden testing, which aggregates rare variants within coding or noncoding loci, enabling the detection of both rare and common variants linked to recovery. Since the pilot GWAS, we now gathered more DNA and outcome data, with currently >8,000 aSAH cases. WGS is available or funded for 1,104 (including 804 from UK Biobank and 300 from ROAR-DNA). We are currently applying for funds to conduct WGS on the rest.

If you have DNA/blood/data to contribute, and would like to join the study, please click on the picture below: